Ribupatide Yields Up to 17.7% Weight Loss in Phase 3 GEMINI-1 Trial - The American Journal of Managed Care
1fuente
1país
1idioma
13:20detectada el 16/11 (19:20 UTC)
13:20última novedad, 16/11
1noticia
Cadena de publicación
La publicó primero The American Journal of Managed Care (Malasia) el 16/11 a las 13:20 (19:20 UTC).
-
13:2016/11, 19:20 UTC
AJThe American Journal of Managed Care news.google.comRibupatide Yields Up to 17.7% Weight Loss in Phase 3 GEMINI-1 Trial - The American Journal of Managed Care
MY EN Primera
Datos de esta historia: JSON

/file/publisher-c1a3f893382d2b2f8a9aa22a654d9c97/2025/03/c48be762a0714a922bf673ae0bea8ffe.jpg)